dc.rights.license |
Green Published, Bronze |
|
dc.date.accessioned |
2021-06-03T08:21:08Z |
|
dc.date.available |
2021-06-03T08:21:08Z |
|
dc.date.issued |
2020 |
|
dc.identifier.issn |
2233-8276 |
|
dc.identifier.uri |
www.doi.org/10.5415/apallergy.2020.10.e29 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/95311 |
|
dc.description |
Bu yayın 06.11.1981 tarihli ve 17506 sayılı Resmî Gazete’de yayımlanan 2547 sayılı Yükseköğretim Kanunu’nun 4/c, 12/c, 42/c ve 42/d maddelerine dayalı 12/12/2019 tarih, 543 sayılı ve 05 numaralı Üniversite Senato Kararı ile hazırlanan Sakarya Üniversitesi Açık Bilim ve Açık Akademik Arşiv Yönergesi gereğince açık akademik arşiv sistemine açık erişim olarak yüklenmiştir. |
|
dc.description.abstract |
Background: Acetylsalicylic acid/aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used drugs that may cause hypersensitivity reactions in a substantial proportion of patients. Physicians ought to be aware of these situations.
Objective: We aimed to present the clinical characteristics and rates of tolerability to cyclooxygenase (COX)-2 inhibitor analgesics in patients who had admitted due to multiple cross-reactive type of NSAID hypersensitivity.
Methods: The files of the patients who had admitted with multiple NSAIDs-induced symptoms were investigated retrospectively. Age, sex, underlying diseases, clinical manifestation, skin test results, and drug provocation test results were analyzed.
Results: In 105 patients with multiple cross-reactive type of NSAID hypersensitivity, we found the rate of cross-reactivity to any of the relatively safe alternatives including paracetamol, meloxicam, and nimesulide to be 16.1%. The rate of cross-reactivity to these relatively safe drugs was significantly higher in patients with a history of anaphylaxis induced by NSAID intake (p= 0.006).
Conclusion: The diagnosis of COX-1-mediated multiple NSAID hypersensitivity can be often established with a detailed history. Although rare, severe hypersensitivity reactions may be observed in these patients. Undesired situations for both patients and physicians may be avoided by testing relatively safe paracetamol and COX-2 inhibitors in experienced centers. |
|
dc.language |
English |
|
dc.language.iso |
İngilizce |
|
dc.publisher |
ASIA PACIFIC ASSOC ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY |
|
dc.relation.isversionof |
10.5415/apallergy.2020.10.e29 |
|
dc.rights |
info:eu-repo/semantics/openAccess |
|
dc.subject |
CLASSIFICATION |
|
dc.subject |
ASPIRIN |
|
dc.subject |
NSAIDS |
|
dc.subject |
ACETAMINOPHEN |
|
dc.subject |
INTOLERANCE |
|
dc.subject |
MANAGEMENT |
|
dc.subject |
DIAGNOSIS |
|
dc.subject |
Cyclooxygenase-2 inhibitors |
|
dc.subject |
Hypersensitivity |
|
dc.subject |
Nonnarcotic analgesics |
|
dc.subject |
Nonsteroidal anti-inflammatory agents |
|
dc.subject |
Paracetamol |
|
dc.title |
Tolerability to paracetamol and preferential COX-2 inhibitors in patients with cross-reactive nonsteroidal anti-inflammatory drugs hypersensitivity |
|
dc.type |
Article |
|
dc.contributor.authorID |
Tulumen Ozturk, Raziye/0000-0001-9503-661X |
|
dc.contributor.authorID |
Ekerbicer, Hasan Cetin/0000-0003-0064-3893 |
|
dc.identifier.volume |
10 |
|
dc.relation.journal |
ASIA PACIFIC ALLERGY |
|
dc.identifier.issue |
3 |
|
dc.identifier.wos |
WOS:000557016600006 |
|
dc.identifier.doi |
10.5415/apallergy.2020.10.e29 |
|
dc.identifier.eissn |
2233-8268 |
|
dc.contributor.author |
Terzioglu, Kadriye |
|
dc.contributor.author |
Sancar, Ozgur |
|
dc.contributor.author |
Ekerbicer, Hasan Cetin |
|
dc.contributor.author |
Ozturk, Raziye Tulumen |
|
dc.contributor.author |
Epozturk, Kursat |
|
dc.relation.publicationcategory |
Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı |
|
dc.identifier.pmıd |
32789114 |
|